Remove Insurance Remove Magazine Remove Pharmaceutical Companies
article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Large pharmaceutical companies such as AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications, accounting for 63% of licensing deals between 2021 and 2025 year-to-date. Can pharma tariffs “Make America Manufacture Again”? ASOs accounted for more than half ($3.54

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

MHRA approves needle-free adrenaline nasal spray for anaphylaxis

Pharmaceutical Technology

Developed by US biotech ARS Pharmaceuticals and under exclusive license in the UK by Danish pharmaceutical company ALK-Abelló, the single-dose nasal spray is indicated for use in adults and children weighing over 30kg and delivers its entire contents (2mg) upon activation.

article thumbnail

Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade

Pharmaceutical Technology

More specifically, the Indian Pharmaceutical Alliance, an organisation representing the country’s largest pharmaceutical companies, has urged the government to reduce import tariffs from the current 10% to zero for pharmaceutical imports from the US. Can pharma tariffs “Make America Manufacture Again”?

article thumbnail

Lupin and Zentiva in licence and supply deal for Certolizumab Pegol

Pharmaceutical Technology

Zentiva Group has entered into a licence and supply agreement with pharmaceutical company Lupin for the commercialisation of the latter’s biosimilar Certolizumab Pegol, a tumour necrosis factor alpha (TNFα) inhibitor medicine, across several markets. Credit: Zentiva Group, a.s.

article thumbnail

UK government targets manufacturing as it eyes £41bn life science sector growth

Pharmaceutical Technology

The initiative comes at a crucial time, as British pharmaceutical companies are significantly increasing their investments in the United States. Outlaid via the Life Sciences Innovative Manufacturing Fund (LSMIF), the investment will aim to expand the UK’s manufacturing capabilities and supply chain security.

article thumbnail

Uruguay progresses towards developing its first regulatory agency

Pharmaceutical Technology

The government therefore is advocating for the creation of the new drug regulatory agency to expedite economic growth, streamline drug approvals and attract international pharmaceutical companies to invest in the country. Give your business an edge with our leading industry insights.